The FDA proposed changes to simplify registration for advanced distributed manufacturing establishments using a hub-and-spoke model, aiming to reduce administrative burden when multiple manufacturing units operate under a single quality oversight framework. The proposal would allow distributed manufacturers to register as one establishment and would clarify requirements for certain foreign sites supplying components into the U.S. supply chain. In parallel, regulatory policy discussions continue to move fast around manufacturing oversight and evidence requirements, including how agencies treat emerging manufacturing modalities and distributed operations. For biotech and CDMOs, the immediate impact is operational: fewer repetitive registrations and clearer oversight expectations can reduce time-to-change while strengthening supply-chain visibility for regulators.